topic

Fibrolamellar carcinoma transcriptomic-based treatment prediction: complete response after nivolumab and ipilimumab
Raanan Berger, Gal Dinstag, Omer Tirosh, Eyal Schiff, David Kleiner, Kenneth D Aldape, Eytan Ruppin, Tuvik Beker, Razelle Kurzrock

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005620; DOI: 10.1136/jitc-2022-005620
Modeling resistance of colorectal peritoneal metastases to immune checkpoint blockade in humanized mice
Emre Küçükköse, Balthasar A Heesters, Julien Villaudy, André Verheem, Madalina Cercel, Susan van Hal, Sylvia F Boj, Inne H M Borel Rinkes, Cornelis J A Punt, Jeanine M L Roodhart, Jamila Laoukili, Miriam Koopman, Hergen Spits, Onno Kranenburg

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005345; DOI: 10.1136/jitc-2022-005345
Dasatinib for treatment of CAR T-cell therapy-related complications
Katharina Baur, Dominik Heim, Astrid Beerlage, Anna S Poerings, Bastian Kopp, Michael Medinger, Jan C Dirks, Jakob R Passweg, Andreas Holbro

Journal for ImmunoTherapy of Cancer Dec 2022, 10 (12) e005956; DOI: 10.1136/jitc-2022-005956
GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway
Dawei Rong, Yuliang Wang, Li Liu, Hengsong Cao, Tian Huang, Hanyuan Liu, Xiaopei Hao, Guangshun Sun, Guoqiang Sun, Zhiying Zheng, Junwei Kang, Yongxiang Xia, Ziyi Chen, Weiwei Tang, Xuehao Wang

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e005126; DOI: 10.1136/jitc-2022-005126
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023
Monika Joshi, Leonard Tuanquin, Junjia Zhu, Vonn Walter, Todd Schell, Matthew Kaag, Deepak Kilari, Jiangang Liao, Sheldon L Holder, Hamid Emamekhoo, Alexander Sankin, Suzzane Merrill, Hong Zheng, Joshua Warrick, Ralph Hauke, Benjamin Gartrel, Mark Stein, Joseph Drabick, David J Degraff, Yousef Zakharia

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e006551; DOI: 10.1136/jitc-2022-006551
TIPE2 deletion improves the therapeutic potential of adoptively transferred NK cells
Jiacheng Bi, Chen Huang, Xiaomeng Jin, Chaoyue Zheng, Yingying Huang, Xiaohu Zheng, Zhigang Tian, Haoyu Sun

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e006002; DOI: 10.1136/jitc-2022-006002
Clonal expansion of resident memory T cells in peripheral blood of patients with non-small cell lung cancer during immune checkpoint inhibitor treatment
Hyunsu Kim, Sehhoon Park, Kyoung-Yeon Han, Naeun Lee, Hyemin Kim, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Se-Hoon Lee, Woong-Yang Park

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e005509; DOI: 10.1136/jitc-2022-005509
Targeting tumor-associated macrophages for successful immunotherapy of ovarian carcinoma
Iva Truxova, David Cibula, Radek Spisek, Jitka Fucikova

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e005968; DOI: 10.1136/jitc-2022-005968
ANKRD22 is a potential novel target for reversing the immunosuppressive effects of PMN-MDSCs in ovarian cancer
Huanhuan Chen, Keqing Yang, Lingxiao Pang, Jing Fei, Yongliang Zhu, Jianwei Zhou

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e005527; DOI: 10.1136/jitc-2022-005527
Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data
WeiQing Venus So, David Dejardin, Eva Rossmann, Jehad Charo

Journal for ImmunoTherapy of Cancer Feb 2023, 11 (2) e006464; DOI: 10.1136/jitc-2022-006464

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages